Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
POINT Biopharma Global Inc. - Common Stock
(NQ:
PNT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about POINT Biopharma Global Inc. - Common Stock
< Previous
1
2
3
4
Next >
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...
Via
Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
December 19, 2023
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c
Via
Benzinga
Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today?
December 18, 2023
Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-res
Via
Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Recap: POINT Biopharma Global Q3 Earnings
November 13, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Collapse In November
November 17, 2023
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
November 09, 2023
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
October 17, 2023
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to...
Via
PressReach
POINT BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of POINT Biopharma Global, Inc. - PNT
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Stock Market Ends On High Note Even As Yields Soar; Tesla In Focus: Weekly Review
October 06, 2023
A rally attempt continues amid soaring Treasury yields.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Why Point BioPharma Global Stock Skyrocketed 86% This Week
October 05, 2023
Point Biopharma is being acquired by Eli Lilly. Here's what investors need to know.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2023
October 04, 2023
Via
Benzinga
Why Eli Lilly Stock Was Looking Sickly Today
October 03, 2023
Investors weren't necessarily satisfied with their company's latest asset buy.
Via
The Motley Fool
Crude Oil Moves Higher; POINT Biopharma Global Shares Jump
October 03, 2023
U.S. stocks extended losses toward the end of trading, with the S&P 500 falling around 1.5% on Tuesday. The Dow traded down 1.43% to 32,954.84 while the NASDAQ fell 1.98% to 13,044.24. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Shares of Point Biopharma Global Are Soaring Tuesday
October 03, 2023
The company entered into a buyout agreement with Eli Lilly.
Via
The Motley Fool
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 03, 2023
Gainers Vericity, Inc. (NASDAQ: VERY) shares climbed 87.4% to $11.12 after iA Financial Group announced it will acquire the company.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 03, 2023
Via
Benzinga
Nasdaq Down Over 200 Points; US Job Openings Rise In August
October 03, 2023
U.S. stocks extended losses midway through trading, with the Nasdaq Composite falling more than 200 points on Tuesday. The Dow traded down 1.06% to 33,078.27 while the NASDAQ fell 1.60% to 13,094.83....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Point Biopharma Stock Nearly Doubles On Eli Lilly Deal
October 03, 2023
Eli Lilly is spending $1.4 billion on buying Point Biopharma Global Inc. Point Biopharma is a radiopharmaceutical company focused on cancer treatment.
Via
Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq - APRN), Chico’s FAS, Inc. (NYSE - CHS)
October 03, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday
October 03, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session. Vericity, Inc. (NASDAQ: VERY) shares climbed...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Falls Over 100 Points; McCormick Sales Miss Views
October 03, 2023
U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.37% to 33,310.99 while the NASDAQ fell...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Point Biopharma Stock Launches 84% On Eli Lilly's $1.4 Billion Takeover
October 03, 2023
The company is working on targeted radiation therapy with prostate cancer results up next.
Via
Investor's Business Daily
HPQ Stock Alert: HP Just Scored a Double Upgrade From Bank of America
October 03, 2023
HP is in the news Tuesday after shares of HPQ stock got a double upgrade and price target increase from Bank of America this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 03, 2023
Via
Benzinga
Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today?
October 03, 2023
Eli Lilly And Co (NYSE: LLY) agreed to acquire POINT Biopharma Global Inc (NASDAQ: PNT) at $12.50 per share in cash, an aggregate of
Via
Benzinga
Why Is Point Biopharma (PNT) Stock Up 84% Today?
October 03, 2023
Point Biopharma stock is heading higher on Tuesday as investors react to news of Eli Lilly acquiring the shares of PNT for $12.50 each.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.